Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

FORGOTTEN HISTORY: Looking into 4d molecular therapeutics s return on capital employed | History Defined

Benzinga Pro data, 4D Molecular Therapeutics (NASDAQ:FDMT) reported Q4 sales of $92.00 thousand. Earnings fell to a loss of $25.08 million, resulting in a 12.79% decrease from last quarter. 4D Molecular Therapeutics collected $1.37 million in revenue during Q3, but reported earnings showed a $22.24 million loss.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.